June 22, 2018 06:13 AM EDT
Financing

Au­to­lus ex­tends the biotech IPO hot streak, adding $150M and bring­ing 2-day tal­ly to $718M

John Carroll

Editor & Founder

Promis­ing new cell ther­a­py tech can still ex­cite in­vestors.

Au­to­lus ex­tend­ed this week’s hot biotech IPO streak, pric­ing an up­sized pack­age of 8.8 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times